Dr. Tara Tagmyer is a seasoned leader in vaccine research and development, with over 20 years of experience spanning CMC, quality operations, supply chain, and global health strategy. Currently serving as Scientific Director at PATH’s Center for Vaccine Innovation and Access, she leads CMC efforts for novel oral polio vaccine development and clinical supply. Prior to PATH, Dr. Tagmyer spent more than 15 years at Merck where she directed the Vaccine Process Development organization, spearheaded pandemic supply chain responses, oversaw Quality Operations, and provided technical support for live viral vaccines including MMR®II, ProQuad®, and RotaTeq®. Dr. Tagmyer holds a Ph.D. in Molecular Virology and Microbiology from the University of Pittsburgh and a B.S. in Biochemistry/Molecular Biology from Penn State. She is an active contributor to the vaccine community, serving as co-chair for the ECI Vaccine Technology Conference and lecturing at MIT-UCL’s Vaccine Bioprocess Workshop.
